SCHEMBL7355494

SCHEMBL7355494

CC(C)C[C@H](N)C(=O)N1CCOCC1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50
GAA P10253 2/20 0.49
TSHR P16473 1/20 0.47
DPP4 P27487 2/20 0.44
DPP8 Q6V1X1 1/20 0.44
DPP9 Q86TI2 1/20 0.44
DPP7 Q9UHL4 1/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
AIMP2 Q13155 1/20 0.44
MEN1 O00255 1/20 0.44
SLC7A5 Q01650 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
PKM P14618 1/20 0.43
CTSS P25774 4/20 0.43
ALDH1A1 P00352 1/20 0.42
MME P08473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7362073 0.98 CYP3A4 (0.49) CYP3A4CYP2C19GAATSHRDPP4
Hydrochloric Acid SCHEMBL8305307 0.98 CYP3A4 (0.49) CYP3A4CYP2C19GAATSHRDPP4
SCHEMBL170707 0.86 CYP3A4 (0.48) CYP3A4CYP2C19GAATSHRKMT2A
SCHEMBL17152611 0.85 L3MBTL3 (0.44) CYP3A4CYP2C19GAADPP4DPP8
SCHEMBL7817249 0.83 DPP7 (0.51) DPP4DPP8DPP9DPP7SLC7A5
SCHEMBL1707035 0.83 DPP7 (0.51) DPP4DPP8DPP9DPP7SLC7A5
SCHEMBL1707036 0.83 DPP7 (0.51) DPP4DPP8DPP9DPP7SLC7A5
SCHEMBL15124202 0.81 CYP3A4 (0.49) CYP3A4CYP2C19GAATSHRDPP4
SCHEMBL10076132 0.81 CYP3A4 (0.49) CYP3A4CYP2C19GAATSHRDPP4
SCHEMBL18774974 0.81 MMP1 (0.51) DPP4DPP8DPP9DPP7SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462625-B2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2008-12-09 US disclosed
US-20070208049-A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2007-09-06 US disclosed
US-7179815-B2 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2007-02-20 US disclosed
EP-0753003-A1 AZIRIDINE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1997-01-15 EP disclosed
WO-1995028416-A1 AZIRIDINE DERIVATIVES, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208049-A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto GNRHR, GHRHR, LHCGR CYP3A4 1300/4885CYP2C19 541/4885GAA 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.